RS57207B1 - Jedinjenja (tieno[2,3-b][1,5]benzoksazepin-4-il)piperazin-1-ila kao dvostruko delujući h1 inverzni agonisti/5-ht2a antagonisti - Google Patents

Jedinjenja (tieno[2,3-b][1,5]benzoksazepin-4-il)piperazin-1-ila kao dvostruko delujući h1 inverzni agonisti/5-ht2a antagonisti

Info

Publication number
RS57207B1
RS57207B1 RS20180568A RSP20180568A RS57207B1 RS 57207 B1 RS57207 B1 RS 57207B1 RS 20180568 A RS20180568 A RS 20180568A RS P20180568 A RSP20180568 A RS P20180568A RS 57207 B1 RS57207 B1 RS 57207B1
Authority
RS
Serbia
Prior art keywords
benzoxazepin
thieno
piperazin
compounds
inverse agonists
Prior art date
Application number
RS20180568A
Other languages
English (en)
Inventor
Andrew James Ledgard
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of RS57207B1 publication Critical patent/RS57207B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20180568A 2011-07-08 2012-07-02 Jedinjenja (tieno[2,3-b][1,5]benzoksazepin-4-il)piperazin-1-ila kao dvostruko delujući h1 inverzni agonisti/5-ht2a antagonisti RS57207B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505685P 2011-07-08 2011-07-08
EP12735409.0A EP2729474B1 (en) 2011-07-08 2012-07-02 (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS
PCT/US2012/045254 WO2013009517A1 (en) 2011-07-08 2012-07-02 (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

Publications (1)

Publication Number Publication Date
RS57207B1 true RS57207B1 (sr) 2018-07-31

Family

ID=46513872

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180568A RS57207B1 (sr) 2011-07-08 2012-07-02 Jedinjenja (tieno[2,3-b][1,5]benzoksazepin-4-il)piperazin-1-ila kao dvostruko delujući h1 inverzni agonisti/5-ht2a antagonisti

Country Status (22)

Country Link
US (1) US9481688B2 (sr)
EP (1) EP2729474B1 (sr)
JP (1) JP6050813B2 (sr)
KR (1) KR101582429B1 (sr)
CN (1) CN103703008B (sr)
AU (1) AU2012283035B2 (sr)
BR (1) BR112014000379A2 (sr)
CA (1) CA2840217C (sr)
DK (1) DK2729474T3 (sr)
EA (1) EA023460B1 (sr)
ES (1) ES2665035T3 (sr)
HR (1) HRP20180475T1 (sr)
HU (1) HUE037649T2 (sr)
IN (1) IN2014MN00144A (sr)
LT (1) LT2729474T (sr)
MX (1) MX341132B (sr)
NO (1) NO2729474T3 (sr)
PL (1) PL2729474T3 (sr)
PT (1) PT2729474T (sr)
RS (1) RS57207B1 (sr)
SI (1) SI2729474T1 (sr)
WO (1) WO2013009517A1 (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2943498T3 (pl) * 2013-01-14 2018-01-31 Lilly Co Eli Związki (tieno[2,3-b][1,5]benzoksazepin-4-ylo)piperazyn-1-ylowe jako odwrotni agoniści h1 / antagoniści 5-ht2a o podwójnej aktywności
TW201625644A (zh) 2014-04-29 2016-07-16 美國禮來大藥廠 作為選擇性5-HTA反向促效劑之(噻吩并[2,3-b][1,5]苯并氧氮呯-4-基)哌嗪-1-基化合物
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN108371660B (zh) * 2017-12-14 2020-03-10 五邑大学 一种四氢环戊二烯并吡咯化合物及其衍生物的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
AU775299B2 (en) * 1999-09-29 2004-07-29 Eli Lilly And Company Piperidine derivatives as reuptake inhibitors
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
US7807828B2 (en) * 2005-08-11 2010-10-05 Hypnion, Inc. Olanzapine analogs and methods of use thereof
ES2384036T3 (es) * 2007-03-15 2012-06-28 Andaman Therapeutics, Inc. Compuesto de dibenzo[b,f][1,4]oxazapina
CN102105059B (zh) * 2008-05-27 2015-09-30 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
GB0910009D0 (en) * 2009-06-10 2009-07-22 Glaxo Group Ltd Novel compounds
AR084867A1 (es) * 2011-02-07 2013-07-10 Lilly Co Eli Compuestos de acido [(5h-pirrolo[2,1-c][1,4]benzodiazepin-11-il)piperazin-1-il]-2,2-dimetilpropanoico sustituido como antagonistas de 5-ht/agonistas inversos de actividad dual
ES2650225T3 (es) * 2011-08-30 2018-01-17 Eli Lilly And Company Compuestos (Tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ilo con doble actividad como agonistas inversos de H1/antagonistas de 5-HT2A

Also Published As

Publication number Publication date
ES2665035T3 (es) 2018-04-24
WO2013009517A1 (en) 2013-01-17
HUE037649T2 (hu) 2018-09-28
JP2014518280A (ja) 2014-07-28
BR112014000379A2 (pt) 2017-01-10
IN2014MN00144A (sr) 2015-06-19
EP2729474A1 (en) 2014-05-14
EA023460B1 (ru) 2016-06-30
SI2729474T1 (en) 2018-04-30
US20140121199A1 (en) 2014-05-01
KR20140029512A (ko) 2014-03-10
CN103703008A (zh) 2014-04-02
NO2729474T3 (sr) 2018-08-11
CN103703008B (zh) 2015-11-25
MX341132B (es) 2016-08-09
PT2729474T (pt) 2018-06-05
JP6050813B2 (ja) 2016-12-21
AU2012283035B2 (en) 2015-07-30
AU2012283035A1 (en) 2014-01-16
KR101582429B1 (ko) 2016-01-04
DK2729474T3 (en) 2018-05-22
HRP20180475T1 (hr) 2018-06-15
CA2840217C (en) 2016-03-22
LT2729474T (lt) 2018-05-10
US9481688B2 (en) 2016-11-01
EA201391706A1 (ru) 2014-04-30
MX2014000337A (es) 2014-11-13
PL2729474T3 (pl) 2018-08-31
CA2840217A1 (en) 2013-01-17
EP2729474B1 (en) 2018-03-14

Similar Documents

Publication Publication Date Title
HRP20171724T1 (hr) Imidazo[1,2-b]piridazin derivati kao inhibitori kinaze
ZA201400874B (en) (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS
IL234485A (en) Compounds based on imidazo [2,1 – b] pyridazine
IL227496B (en) Pyrazolo[4,3–b]pyridines are converted as drugs
SG11201402197UA (en) [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
ZA201403441B (en) [1,2,3]triazolo[4,5-d]pyrimidine derivatives as agonists of the cannabinoid
HRP20180475T1 (hr) (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI, DVOJNO AKTIVNI KAO INVERZNI AGONISTI H1/ANTAGONISTI 5-HT2A
IL232717A0 (en) 3-cyanoaryl-h1-pyrrolo[b-3,2]pyridine derivatives
HRP20150469T1 (hr) SUPSTITUIRANI SPOJEVI [(5H-PIROLO[2,1-c][1,4]BENZODIAZEPIN-11-IL)PIPERAZIN-1-IL]-2,2-DIMETILPROPANSKE KISELINE KAO DVOSTRUKO DJELUJUĆI INVERZNI AGONISTI H1/ANTAGONISTI HT2A
SG11201500883YA (en) 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
ZA201504041B (en) (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity h1 inverse agonists/5-ht2a antagonists